
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
Maresca confident he will survive Chelsea slump
-
Mob beats to death man from persecuted Pakistan minority
-
Lebanon says one killed in Israeli strike near Sidon
-
Arsenal's Havertz could return for Champions League final
-
US officials split on Ukraine truce prospects
-
Client brain-dead after Paris cryotherapy session goes wrong
-
Flick demands answers from La Liga for 'joke' schedule
-
'Maddest game' sums up Man Utd career for Maguire
-
Trial opens for students, journalists over Istanbul protests
-
Gaza rescuers say Israeli strikes kill 24 after Hamas rejects truce proposal
-
'Really stuck': Ukraine's EU accession drive stumbles
-
'Not the time to discuss future', says Alonso amid Real Madrid links
-
74 killed in deadliest US attack on Yemen, Huthis say
-
Southgate's ex-assistant Holland fired by Japan's Yokohama
-
Vance meets Meloni in Rome before Easter at the Vatican
-
Ryan Gosling to star in new 'Star Wars' film
-
Hamas calls for pressure to end Israel's aid block on Gaza
-
Russia says Ukraine energy truce over, US mulls peace talks exit
-
58 killed in deadliest US strike on Yemen, Huthis say
-
Museums rethink how the Holocaust should be shown
-
Three dead after deadly spring storm wreaks havoc in the Alps
-
No need for big changes at Liverpool, says Slot
-
Bloody Philippine passion play sees final performance of veteran 'Jesus'
-
New US envoy prays, delivers Trump 'peace' message at Western Wall
-
Postecoglou sticking around 'a little longer' as Spurs show fight in Frankfurt
-
US threatens to withdraw from Ukraine talks if no progress
-
Tears and defiance in Sumy as Russia batters Ukraine border city
-
Russia rains missiles on Ukraine as US mulls ending truce efforts
-
Tokyo leads gains in most Asian markets on trade deal hopes
-
Two missing after deadly spring snowstorm wreaks havoc in the Alps
-
'War has taken everything': AFP reporter returns home to Khartoum
-
US strikes on Yemen fuel port kill 38, Huthis say
-
Slegers targets Lyon scalp in pursuit of Arsenal European glory
-
'Defend ourselves': Refugee girls in Kenya find strength in taekwondo
-
China's manufacturing backbone feels Trump trade war pinch
-
Sri Lankans throng to Kandy for rare display of Buddhist relic
-
Chinese vent anger at Trump's trade war with memes, mockery
-
Heartbroken Brits abandon pets as living costs bite
-
Mongolian LGBTQ youth fight for recognition through music, comedy
-
Cash crunch leaves Syrians queueing for hours to collect salaries
-
Lyon left to regroup for Champions League bid after painful European exit
-
Unravelling Real Madrid face Athletic Bilbao Liga test
-
Napoli disturbing buoyant Inter's peace in Serie A Easter bonanza
-
Disappointed Dortmund chase consistency with Europe at stake
-
Asian markets mixed as traders track tariff talks
-
Yan and Buhai share lead at LA Championship
-
Under fire at debate, Canada PM Carney tries to focus on Trump
-
Liverpool poised for Premier League coronation, Leicester, Ipswich for relegation
-
India's elephant warning system tackles deadly conflict

3M expects to sell fewer Covid-19 masks this year
After seeing sales of medical masks soar during the Covid-19 pandemic, US manufacturer 3M warned Monday that demand is expected to slow sharply this year.
The warning echoes that of other companies like vaccine-maker Pfizer and the CVS drugstore chain that have said pandemic-related sales are likely to soften.
After Covid-19 broke out in 2020, 3M, a conglomerate that makes a wide range of products from Post-it notes to air filters, quickly ramped up output of face masks, which became ubiquitous.
But in its quarterly earnings report Monday, 3M forecast a "decline in Covid-related respirator demand" which it said will weigh on overall sales growth and also dampen earnings.
Honeywell in early February said it sold fewer masks in the fourth quarter compared to the same period in 2020, and sees the slowdown continuing this year, hitting the company's overall sales.
Pfizer, whose vaccine developed with German company BioNTech was the first approved in the United States to counter the deadly virus, warned last week that sales of the jabs would slow in 2022.
But the US pharmaceutical group expects to see sales of its Covid-19 treatment pill to jump to at least $22 billion.
Meanwhile, CVS, which conducted 32 million Covid tests and administered more than 59 million vaccines in 2021, said last week it is expecting vaccinations to drop by 70 to 80 percent and testing to fall by as much as 50 percent.
CVS Chief financial officer Shawn Guertin told analysts the chain should see a "modest" uptick in sales of over-the-counter test kits.
A.Rodriguezv--AMWN